(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 0.6% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 8.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.9%.
10x Genomics's revenue in 2025 is $624,662,000.On average, 9 Wall Street analysts forecast TXG's revenue for 2025 to be $75,932,027,676, with the lowest TXG revenue forecast at $71,306,754,625, and the highest TXG revenue forecast at $76,995,533,875. On average, 9 Wall Street analysts forecast TXG's revenue for 2026 to be $74,826,656,003, with the lowest TXG revenue forecast at $73,006,000,375, and the highest TXG revenue forecast at $77,167,921,125.
In 2027, TXG is forecast to generate $83,965,150,393 in revenue, with the lowest revenue forecast at $77,313,588,351 and the highest revenue forecast at $94,407,877,463.